Literature DB >> 22021035

MUC1 protein expression in tumor cells regulates transcription of proinflammatory cytokines by forming a complex with nuclear factor-κB p65 and binding to cytokine promoters: importance of extracellular domain.

Sandra Cascio1, Lixin Zhang, Olivera J Finn.   

Abstract

MUC1 is a transmembrane glycoprotein abnormally expressed in all stages of development of human adenocarcinomas. Overexpression and hypoglycosylation of MUC1 in cancer cells compared with normal epithelial cells are likely to alter its function and affect the behavior of cancer cells. The extracellular domain, specifically the highly O-glycosylated VNTR (variable number of tandem repeats) region, plays an important role in cell-cell communication; however, we show here that it also participates intracellularly in activation of the NF-κB pathway. Transfection of MUC1(-) tumor cells with cDNA encoding MUC1 with 22 tandem repeats (MUC1/22TR) or two tandem repeats (MUC1/2TR) or two isoforms that lack the VNTR region (MUC1/Z and MUC1/Y) showed that the highest expression levels of NF-κB family members correlated with the presence of VNTR and the highest number of tandem repeats. Because expression of MUC1 with VNTR on tumors was previously associated with chemotactic activity for cells of the innate immune system, we investigated the influence of MUC1 expression on the NF-κB-dependent transcriptional regulation of proinflammatory cytokines. ChIP and real-time PCR experiments revealed that MUC1/22TR up-regulated IL-6 and TNF-α expression by binding to their promoter regions in a NF-κB p65-dependent manner in both MUC1-transfected and human breast cancer cells that express endogenous MUC1. This newly detected complex of MUC1 and p65 is a novel mechanism that tumors can use to promote inflammation and cancer development.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22021035      PMCID: PMC3234962          DOI: 10.1074/jbc.M111.297630

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  23 in total

1.  Interaction of NF-kappaB and NFAT with the interferon-gamma promoter.

Authors:  A Sica; L Dorman; V Viggiano; M Cippitelli; P Ghosh; N Rice; H A Young
Journal:  J Biol Chem       Date:  1997-11-28       Impact factor: 5.157

2.  Clathrin-mediated endocytosis of MUC1 is modulated by its glycosylation state.

Authors:  Y Altschuler; C L Kinlough; P A Poland; J B Bruns; G Apodaca; O A Weisz; R P Hughey
Journal:  Mol Biol Cell       Date:  2000-03       Impact factor: 4.138

3.  Vaccine against MUC1 antigen expressed in inflammatory bowel disease and cancer lessens colonic inflammation and prevents progression to colitis-associated colon cancer.

Authors:  Pamela L Beatty; Sowmya Narayanan; Jean Gariépy; Sarangarajan Ranganathan; Olivera J Finn
Journal:  Cancer Prev Res (Phila)       Date:  2010-03-23

Review 4.  O-linked glycosylation in the mammary gland: changes that occur during malignancy.

Authors:  J M Burchell; A Mungul; J Taylor-Papadimitriou
Journal:  J Mammary Gland Biol Neoplasia       Date:  2001-07       Impact factor: 2.673

5.  Activation of interleukin-6 gene expression through the NF-kappa B transcription factor.

Authors:  T A Libermann; D Baltimore
Journal:  Mol Cell Biol       Date:  1990-05       Impact factor: 4.272

Review 6.  Mucins in cancer: function, prognosis and therapy.

Authors:  Donald W Kufe
Journal:  Nat Rev Cancer       Date:  2009-12       Impact factor: 60.716

Review 7.  Tumour necrosis factor alpha: a potential target for the therapy of solid tumours.

Authors:  Peter W Szlosarek; Frances R Balkwill
Journal:  Lancet Oncol       Date:  2003-09       Impact factor: 41.316

8.  Structure of a tumor associated antigen containing a tandemly repeated immunodominant epitope.

Authors:  J D Fontenot; S V Mariappan; P Catasti; N Domenech; O J Finn; G Gupta
Journal:  J Biomol Struct Dyn       Date:  1995-10

9.  Kappa B-specific DNA binding proteins: role in the regulation of human interleukin-2 gene expression.

Authors:  B Hoyos; D W Ballard; E Böhnlein; M Siekevitz; W C Greene
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

Review 10.  MUC1 and the immunobiology of cancer.

Authors:  Joyce Taylor-Papadimitriou; Joy M Burchell; Timothy Plunkett; Rosalind Graham; Isabel Correa; David Miles; Michael Smith
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.698

View more
  36 in total

1.  Altered RNA Splicing by Mutant p53 Activates Oncogenic RAS Signaling in Pancreatic Cancer.

Authors:  Luisa F Escobar-Hoyos; Alex Penson; Ram Kannan; Hana Cho; Chun-Hao Pan; Rohit K Singh; Lisa H Apken; G Aaron Hobbs; Renhe Luo; Nicolas Lecomte; Sruthi Babu; Fong Cheng Pan; Direna Alonso-Curbelo; John P Morris; Gokce Askan; Olivera Grbovic-Huezo; Paul Ogrodowski; Jonathan Bermeo; Joseph Saglimbeni; Cristian D Cruz; Yu-Jui Ho; Sharon A Lawrence; Jerry P Melchor; Grant A Goda; Karen Bai; Alessandro Pastore; Simon J Hogg; Srivatsan Raghavan; Peter Bailey; David K Chang; Andrew Biankin; Kenneth R Shroyer; Brian M Wolpin; Andrew J Aguirre; Andrea Ventura; Barry Taylor; Channing J Der; Daniel Dominguez; Daniel Kümmel; Andrea Oeckinghaus; Scott W Lowe; Robert K Bradley; Omar Abdel-Wahab; Steven D Leach
Journal:  Cancer Cell       Date:  2020-06-18       Impact factor: 31.743

2.  Proteomic signatures of acquired letrozole resistance in breast cancer: suppressed estrogen signaling and increased cell motility and invasiveness.

Authors:  Syreeta L Tilghman; Ian Townley; Qiu Zhong; Patrick P Carriere; Jin Zou; Shawn D Llopis; Lynez C Preyan; Christopher C Williams; Elena Skripnikova; Melyssa R Bratton; Qiang Zhang; Guangdi Wang
Journal:  Mol Cell Proteomics       Date:  2013-05-23       Impact factor: 5.911

3.  Serum carbohydrate antigen 153 and renal function in patients with type 2 diabetes mellitus.

Authors:  You-Fan Peng; Hao Lin; Man-Man Han; Ling Li
Journal:  J Clin Lab Anal       Date:  2018-04-27       Impact factor: 2.352

Review 4.  Emerging potential of natural products for targeting mucins for therapy against inflammation and cancer.

Authors:  Muzafar A Macha; Shiv Ram Krishn; Rahat Jahan; Kasturi Banerjee; Surinder K Batra; Maneesh Jain
Journal:  Cancer Treat Rev       Date:  2015-01-14       Impact factor: 12.111

5.  Low reactivity of tumor MUC1-binding natural anti-α-galactoside antibody is a risk factor for breast cancer.

Authors:  Jessy John; Kurian Cherian; Thomas Abraham; Padinjaradath S Appukuttan
Journal:  Exp Biol Med (Maywood)       Date:  2020-01-19

Review 6.  Genetic variants of mucins: unexplored conundrum.

Authors:  Sushil Kumar; Eric Cruz; Suhasini Joshi; Asish Patel; Rahat Jahan; Surinder K Batra; Maneesh Jain
Journal:  Carcinogenesis       Date:  2017-07-01       Impact factor: 4.944

Review 7.  Host response in tumor diagnosis and prognosis: importance of immunologists and pathologists alliance.

Authors:  Olivera J Finn
Journal:  Exp Mol Pathol       Date:  2012-10-23       Impact factor: 3.362

8.  14-3-3z sequesters cytosolic T-bet, upregulating IL-13 levels in TC2 and CD8+ lymphocytes from patients with scleroderma.

Authors:  Sandra Cascio; Thomas A Medsger; William F Hawse; Simon C Watkins; Christine Milcarek; Larry W Moreland; Robert A Lafyatis; Patrizia Fuschiotti
Journal:  J Allergy Clin Immunol       Date:  2017-11-15       Impact factor: 10.793

9.  Mucin-1 Increases Renal TRPV5 Activity In Vitro, and Urinary Level Associates with Calcium Nephrolithiasis in Patients.

Authors:  Mingzhu Nie; Manjot S Bal; Zhufeng Yang; Jie Liu; Carolina Rivera; Andrea Wenzel; Bodo B Beck; Khashayar Sakhaee; Denise K Marciano; Matthias T F Wolf
Journal:  J Am Soc Nephrol       Date:  2016-04-01       Impact factor: 10.121

10.  Mammalian adenylyl cyclase-associated protein 1 (CAP1) regulates cofilin function, the actin cytoskeleton, and cell adhesion.

Authors:  Haitao Zhang; Pooja Ghai; Huhehasi Wu; Changhui Wang; Jeffrey Field; Guo-Lei Zhou
Journal:  J Biol Chem       Date:  2013-06-04       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.